Catalyst
Slingshot members are tracking this event:
Keryx (KERX) Announces Phase III Results Evaluating Auryxia for the Treatment of Iron Deficiency Anemia in Patients With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KERX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iii Results, Stage 3-5, Non-dialysis-dependent, Chronic Kidney Disease, Oral Iron-based Treatment, Iron Deficiency Anemia, Ferric Citrate
